Page last updated: 2024-10-15

antiamoebin

Description

antiamoebin: antiprotozoal, anthelmintic antibiotic produced by the fungus Emericellopsis poonensis Thirum [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16132282
MeSH IDM0049224

Synonyms (7)

Synonym
12692-85-2
antiamoebin i
antiamoebin ii
antibiotic tu 165
antiamebin
antiamoebin
Q15634104

Research Excerpts

Overview

Antiamoebin I is a membrane-active peptaibol produced by fungi of the species Emericellopsis which is capable of forming ion channels in membranes. It acts as an antiamoebic agent, but does not effectively haemolyze erythrocytes even though it does exhibit membrane-modifying activity.

ExcerptReference
"Antiamoebin I (Aam-I) is a membrane-active peptaibol antibiotic isolated from fungal species belonging to the genera Cephalosporium, Emericellopsis, Gliocladium, and Stilbella. "( Peptaibol antiamoebin I: spatial structure, backbone dynamics, interaction with bicelles and lipid-protein nanodiscs, and pore formation in context of barrel-stave model.
Arseniev, AS; Gizatullina, AK; Kirpichnikov, MP; Lyukmanova, EN; Ovchinnikova, TV; Paramonov, AS; Shenkarev, ZO; Tagaev, AA; Telezhinskaya, IN; Yakimenko, ZA; Zhuravleva, AV, 2013
)
"Antiamoebin I is a membrane-active peptaibol produced by fungi of the species Emericellopsis which is capable of forming ion channels in membranes. "( Solution NMR studies of antiamoebin, a membrane channel-forming polypeptide.
Driscoll, PC; Galbraith, TP; Harris, R; Wallace, BA, 2003
)
"Antiamoebin (AAM) is a polypeptide antibiotic that is capable of forming ion channels in phospholipid membranes: planar bilayer studies have suggested the channels are octamers. "( The peptaibol antiamoebin as a model ion channel: similarities to bacterial potassium channels.
O'Reilly, AO; Wallace, BA,
)
"Antiamoebin I (Aam-I) is a membrane-active peptaibol antibiotic isolated from fungal species belonging to the genera Cephalosporium, Emericellopsis, Gliocladium, and Stilbella. "( Antiamoebin I in methanol solution: rapid exchange between right-handed and left-handed 3(10)-helical conformations.
Arseniev, AS; Bocharov, EV; Kudelina, IA; Nadezhdin, KD; Ovchinnikova, TV; Paramonov, AS; Shenkarev, ZO; Skladnev, DA; Tagaev, AA; Yakimenko, ZA, 2007
)
"Antiamoebin is a member of the peptaibol family of polypeptides and has a unique antibiotic activity: it acts as an antiamoebic agent, but does not effectively haemolyze erythrocytes even though it does exhibit membrane-modifying activity."( The structure and function of antiamoebin I, a proline-rich membrane-active polypeptide.
Blundell, TL; Oliva, G; Pattabhi, V; Snook, CF; Wallace, BA; Wood, SF; Woolley, GA, 1998
)
"Antiamoebin is a 16-residue polypeptide whose crystal structure and lytic activity in membrane vesicles have recently been reported. "( Antiamoebin can function as a carrier or as a pore-forming peptaibol.
Duclohier, H; Snook, CF; Wallace, BA, 1998
)
"Antiamoebin is shown to be an effective uncoupler of oxidative phosphorylation in rat liver mitochondria, providing evidence for its membrane-modifying activity."( Membrane channel forming polypeptides. Molecular conformation and mitochondrial uncoupling activity of antiamoebin, an alpha-aminoisobutyric acid containing peptide.
Balaram, P; Das, MK; Raghothama, S, 1986
)

Effects

ExcerptReference
"The antiamoebin molecule has a bent helical conformation very similar to that established for Leu-zervamicin, despite a significantly different sequence for residues 1-8."( Crystal structure of the channel-forming polypeptide antiamoebin in a membrane-mimetic environment.
Balaram, P; Karle, IL; Mishra, VK; Perozzo, MA, 1998
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (22.22)18.7374
1990's7 (25.93)18.2507
2000's9 (33.33)29.6817
2010's4 (14.81)24.3611
2020's1 (3.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]